Eli Lilly’s Surge in Weight Loss Drug Market
Eli Lilly has captured 60% of the U.S. market for GLP-1 weight loss drugs, overtaking Novo Nordisk, as the weight loss drug sector is projected to reach nearly $100 billion by 2030. Following approvals for its oral weight loss drug, Foundayo, in April, and promising phase 3 trial results for retatrutide, Lilly’s stock has surged over 18% in May, recently surpassing $1,000 per share.
As the pharmaceutical giant continues to innovate within a high-growth field, it has positioned itself for sustained revenue gains similar to those seen with Nvidia, which has experienced a 400% rise in stock value over the last three years. The latest market dynamics underscore Lilly’s strategy to expand its weight loss portfolio, reinforcing its dominant market position.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
